Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics, Inc. (CADL) General Counsel Maria Ostrovsky was granted 315,000 stock options on November 3, 2026, at an exercise price of $8.82 per share. Her reported post-transaction option position was 315,000. Twenty-five percent vest and become exercisable on November 3, 2027; the remainder vests in 36 equal monthly installments, subject to her continued service on each vesting date.
Candel Therapeutics, Inc. director Nicoletta Loggia acquired 380 stock options on September 30, 2026, covering 380 shares of common stock. The award was granted in lieu of normal quarterly cash payments and was fully vested at grant.
Candel Therapeutics, Inc. director Joseph C. Papa received a grant of 1,325 stock options on September 30, 2026, in lieu of normal quarterly cash payments. The underlying award quantity was fully vested at grant. The options have an exercise price of $10.44 per share and expire September 30, 2036; Papa’s reported option position after the grant was 1,325.
Candel Therapeutics, Inc. (CADL) granted director Paul B. Manning 2,189 stock options on September 30, 2026, covering 2,189 common shares. The award was granted in lieu of normal quarterly cash payments and was fully vested at grant. The options have a $10.44 exercise price and expire September 30, 2036.
Candel Therapeutics, Inc. (CADL) reported that Chief Executive Officer and director Paul Peter Tak exercised options and sold shares of common stock. On September 10, 2026, he exercised options to acquire 125,000 shares at $1.55 per share, and on the same day sold 220,866 shares at a weighted average price of $11.4997 per share in multiple trades. On September 11, 2026, he sold an additional 59,379 shares at a weighted average price of $10.4564 per share in multiple trades. The option exercise related to an award expiring on October 10, 2030, and following that exercise 1,638,968 option-linked shares remained outstanding. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 and modified on June 11, 2026.
Candel Therapeutics, Inc. (CADL) received a notice that stockholder Paul Peter Tak intends to sell up to 280,245 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $3,410,581.65 for these shares and references 76,518,565 shares outstanding of the same class.
The shares derive from equity compensation: 125,000 shares from stock options to be exercised on September 10, 2026, 12,900 shares from previously exercised options dated November 21, 2024, and 142,345 shares from restricted stock units with an acquisition date of July 9, 2024. The notice states the securities to be sold were acquired upon the vesting of restricted stock units during the period from July 9, 2024 through January 14, 2025.
Candel Therapeutics, Inc. (CADL) reported that director Martine Zimmermann received a grant of stock options covering 64,000 shares of Common Stock on September 8, 2026. The options have an exercise price of $12.60 per share and expire on September 8, 2036. The award vests in thirty-six equal monthly installments, subject to her continued service, and represents her direct beneficial ownership of these derivative securities. No Rule 10b5-1 trading plan is reported for this grant.
Candel Therapeutics, Inc. (CADL) reported that Martine Zimmermann, a director of the company, filed an initial statement of beneficial ownership on Form 3. The filing lists no equity holdings or reportable transactions in Candel Therapeutics securities at this time.
Candel Therapeutics, Inc. (CADL) expanded its Board of Directors from ten to eleven members and appointed Martine Zimmermann, Pharm.D. as a Class III independent director, effective September 8, 2026, with a term expiring at the 2027 annual stockholders’ meeting. Her compensation includes an option to purchase 64,000 shares of common stock, vesting monthly over three years, and a $40,000 annual cash retainer, paid quarterly and pro rated for service. Candel highlights Dr. Zimmermann’s more than 30 years of global regulatory and quality experience as it prepares for a planned Biologics License Application (BLA) submission for aglatimagene besadenovec in the fourth quarter of 2026 and potential commercial readiness. The company also reiterates that more than 1,000 patients have received aglatimagene in clinical trials and summarizes multiple FDA designations, including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy, for its lead programs.